Category Archives: BioUtah News
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO
ARUP Launches pTau 217 Blood Test To Detect Alzheimer’s Disease Pathology
The biomarker pTau 217 is associated with Alzheimer’s disease pathology and can be detected in plasma, providing a minimally invasive option to support other diagnostic tests.
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants.
Congresssional Staffer Tours
Congresssional Staffer Tours
Nelson Labs Celebrates 40 Years of Excellence in Science and Service
Nelson Labs Celebrates 40 Years of Excellence in Science and Service
Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
Salt Lake City, UT – April 9, 2025 – DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that the double-blind, peer-reviewed article, “Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration—Results […]
BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD
Huntsman Cancer Institute at the University of Utah (the U) broke ground on its second Comprehensive Cancer Center on Tuesday, April 8, advancing construction of a new facility wholly dedicated to delivering prevention, hope, and healing to cancer patients. Situated in Vineyard, in the heart of Utah County, the Huntsman Cancer Institute site will reduce […]
The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors
Hutt Brings Decades of Regulatory Insight to Help Advance Nanoparticle Technology Platform SALT LAKE CITY, Utah (April 9, 2025) — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced the appointment of Peter Barton Hutt, former FDA Chief Counsel, to its board of directors. Widely […]
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small […]
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has […]
Merit Medical Launches the Ventrax™ Delivery System
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing […]
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]
